Current efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Gleason, Rudolph L ^a,b   Caulk, Alexander W ^a   Seifu, Daniel ^c   Parker, Ivana ^b   Vidakovic, Brani ^b   Getenet, Helena ^c   Assefa, Getachew ^c   Amogne, Wondwossen ^c  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; BIOLOGICAL MARKER; LOPINAVIR; RITONAVIR;

ADULT; AGE; AORTA PRESSURE; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTERY DILATATION; ARTICLE; ATHEROSCLEROSIS; BODY FAT DISTRIBUTION; BODY MASS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE DURATION; DRUG USE; DYSLIPIDEMIA; ETHIOPIA; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PULSE WAVE; SELF REPORT; SKINFOLD THICKNESS; WAIST HIP RATIO; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; COMPLICATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ATHEROSCLEROSIS; BENZOXAZINES; BIOMARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ETHIOPIA; FEMALE; HEART RATE; HIV INFECTIONS; HIV-1; HUMANS; LIPODYSTROPHY; LOPINAVIR; MALE; MIDDLE AGED; NEVIRAPINE; PULSE WAVE ANALYSIS; RITONAVIR; TRIGLYCERIDES;

EID: 84928670685     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117125     Document Type: Article

References (87)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm D, et al. (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353: 2093-2099. PMID: 10382692
2. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D (2003) Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17: 2479-2486. PMID: 14600519
3. Friis-Moller N, Sabin C, Weber R, D"Arminio Monforte A, El-Sadr W, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine 349: 1993-2003. PMID: 14627784
4. Maggi P, Lillo A, Perilli F, Maserati R, Chirianni A (2004) Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 18: 1023-1028. PMID: 15096805
5. Sevastianova K, Sutinen J, Westerbacka J, Ristola M, Yki-Jarvinen H (2005) Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy. Antivir Ther 10: 925-935. PMID: 16430198
6. van Vonderen M, Hassink E, van Agtmael M, Stehouwer C, Danner S, et al. (2009) Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. Journal of Infectious Diseases 199: 1186-1194. doi: 10.1086/597475 PMID: 19275490
7. Hsue P, Lo J, Franklin A, Bolger A, Martin J, et al. (2004) Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109: 1603-1608. PMID: 15023877
8. Stein J, Klein M, Bellehumeur J, McBride P, Wiebe D, et al. (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104: 257-262. PMID: 11457741
9. Shankar S, Dube M, Gorski J, Klaunig J, Steinberg H (2005) Indinavir impairs endothelial function in healthy HIV-negative men. American Heart Journal 150: 933. PMID: 16290967
10. Fontas E, van Leth F, Sabin C, Friis-Moller N, Rickenbach M, et al. (2004) Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? Journal of Infectious Diseases 189: 1056-1074. PMID: 14999610
11. Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, et al. (2009) Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 23: 2021-2027. doi: 10.1097/QAD.0b013e32832e7140 PMID: 19542863
12. UNAIDS (2012) Report on the Global AIDS Epidemic.
13. van Wijk JP, de Koning EJ, Cabezas MC, Joven J, op't Roodt J, et al. (2006) Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. Journal of the American College of Cardiology 47: 1117-1123. PMID: 16545639
14. Johnsen S, Dolan SE, Fitch KV, Kanter JR, Hemphill LC, et al. (2006) Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 91: 4916-4924. PMID: 17003092
15. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, et al. (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104: 257-262. PMID: 11457741
16. Shankar SS, Dube MP, Gorski JC, Klaunig JE, Steinberg HO (2005) Indinavir impairs endothelial function in healthy HIV-negative men. American Heart Journal 150: 933. PMID: 16290967
17. Blanco JJ, Garcia IS, Cerezo JG, de Rivera JM, Anaya PM, et al. (2006) Endothelial function in HIV-infected patients with low or mild cardiovascular risk. Journal of Antimicrobial Chemotherapy 58: 133-139. PMID: 16702174
18. Fisher SD, Miller TL, Lipshultz SE (2006) Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis 185: 1-11. PMID: 16297390
19. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, et al. (2003) Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17: 1179-1193. PMID: 12819520
20. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, et al. (2010) Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Journal of Infectious Diseases 201: 318-330. doi: 10.1086/649897 PMID: 20039804
21. Currier JS, Kendall MA, Henry WK, Alston-Smith B, Torriani FJ, et al. (2007) Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 21: 1137-1145. PMID: 17502724
22. Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, et al. (2005) Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 19: 927-933. PMID: 15905673
23. Grubb JR, Dejam A, Voell J, Blackwelder WC, Sklar PA, et al. (2006) Lopinavir-ritonavir: effects on endothelial cell function in healthy subjects. Journal of Infectious Diseases 193: 1516-1519. PMID: 16652279
24. Nolan D, Watts GF, Herrmann SE, French MA, John M, et al. (2003) Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM 96: 825-832. PMID: 14566037
25. Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, et al. (2006) Endothelial function in HIV-infected persons. Clinical Infectious Diseases 42: 1325-1332. PMID: 16586393
26. Arnet D, Evans G, RileyW(1994) Arterial stiffness: a new cardiovascular risk factor? American Journal of Epidemiology 140: 669-682. PMID: 7942769
27. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, et al. (2011) T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis.
28. Seaberg EC, Benning L, Sharrett AR, Lazar JM, Hodis HN, et al. (2010) Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke 41: 2163-2170. doi: 10.1161/STROKEAHA.110.583856 PMID: 20798374
29. Hansen L, Parker I, Roberts LM, Sutliff R, Platt M, et al. (2013) Azidothymidine (AZT) leads to arterial stiffening and intima-media thickening in mice. Journal of Biomechanics In Press.
30. van Vonderen M, Smulders Y, Stehouwer C, Danner S, Gundy C, et al. (2009) Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. Journal of Acquired Immune Deficiency Syndromes 50: 153-161. doi: 10.1097/QAI.0b013e31819367cd PMID: 19131894
31. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, et al. (2009) Predictive value of brachial flowmediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 120: 502-509. doi: 10.1161/CIRCULATIONAHA.109.864801 PMID: 19635967
32. Oliviero U, Bonadies G, Apuzzi V, Foggia M, Bosso G, et al. (2009) Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis 204: 586-589. doi: 10.1016/j.atherosclerosis.2008.10.012 PMID: 19084229
33. Torriani F, Komarow L, Parker R, Cotter B, Currier J, et al. (2008) Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. Journal of the American College of Cardiology 52: 569-576. doi: 10.1016/j.jacc.2008.04.049 PMID: 18687253
34. Gupta SK, Shen C, Moe SM, Kamendulis LM, Goldman M, et al. (2012) Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PloS one 7: e45716. doi: 10.1371/journal.pone.0045716 PMID: 23029197
35. Masiá M, Padilla S, García N, Jarrin I, Bernal E, et al. (2010) Endothelial function is impaired in HIV-infected patients with lipodystrophy. Antiviral therapy 15: 101-110. doi: 10.3851/IMP1491 PMID: 20167996
36. Chironi G, Escaut L, Gariepy J, Cogny A, Teicher E, et al. (2003) Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 32: 490-493. PMID: 12679699
37. Mercie P, Thiebaut R, Aurillac-Lavignolle V, Pellegrin J, Yvorra-Vives M, et al. (2005) Carotid intimamedia thickness is slightly increased over time in HIV-1-infected patients. HIV Med 6: 380-387. PMID: 16268819
38. Lorenz M, Stephan C, Harmjanz A, Staszewski S, Buehler A, et al. (2008) Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 196: 720-726. PMID: 17275008
39. Hsue P, Hunt P, Schnell A, Kalapus S, Hoh R, et al. (2009) Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 23: 1059-1067. doi: 10.1097/ QAD.0b013e32832b514b PMID: 19390417
40. Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA (2011) Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 214: 468-473. doi: 10.1016/j. atherosclerosis.2010.11.013 PMID: 21130995
41. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, et al. (2011) T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. The Journal of infectious diseases 203: 452-463. doi: 10.1093/infdis/jiq071 PMID: 21220772
42. Longenecker C, Funderburg N, Jiang Y, Debanne S, Storer N, et al. (2013) Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med.
43. Ross AC, O'Riordan MA, Storer N, Dogra V, McComsey GA (2010) Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis 211: 492-498. doi: 10.1016/j.atherosclerosis.2010.04.008 PMID: 20471650
44. Falcone EL, Mangili A, Skinner S, Alam A, Polak JF, et al. (2011) Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Antiviral therapy 16: 1-8. doi: 10. 3851/IMP1682 PMID: 21311103
45. Kline ER, Sutliff RL (2008) The role of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med 56: 752-769. doi: 10.1097/JIM.0b013e3181788d15 PMID: 18525451
46. Hansen L, Parker I, Roberts LM, Sutliff RL, Platt MO, et al. (2013) Azidothymidine (AZT) leads to arterial stiffening and intima-media thickening in mice. J Biomech 46: 1540-1547. doi: 10.1016/j.jbiomech. 2013.03.021 PMID: 23623314
47. Sutliff R, Dikalov S, Weiss D, Parker J, Raidel S, et al. (2002) Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. American Journal of Physiology: Heart and Circulatory Physiology 283: H2363-H2370. PMID: 12388299
48. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, et al. (2011) Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 25: 1289-1298. doi: 10.1097/QAD.0b013e328347fa16 PMID: 21516027
49. Kowalska JD, Kirk O, Mocroft A, Hoj L, Friis-Moller N, et al. (2010) Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir. HIV medicine 11: 200-208. doi: 10.1111/j.1468-1293.2009.00763.x PMID: 19863618
50. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, et al. (2010) Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. The Journal of infectious diseases 201: 318-330. doi: 10.1086/649897 PMID: 20039804
51. Lundgren J, Neuhaus J, Babiker A, Cooper D, Duprez D, et al. (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22: F17-24. doi: 10.1097/QAD.0b013e32830fe35e PMID: 18753925
52. Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, et al. (2011) No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 52: 929-940.
53. Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, et al. (2009) Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 23: 2021-2027. doi: 10.1097/QAD.0b013e32832e7140 PMID: 19542863
54. Sutliff RL, Dikalov S, Weiss D, Parker J, Raidel S, et al. (2002) Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. American Journal of Physiology: Heart and Circulatory Physiology 283: H2363-H2370. PMID: 12388299
55. Hansen L, Kennedy I, Sutliff R, Platt M, Gleason R (In Preparation) AZT induces intima-medial thickening, endothelial dysfunction, and arterial stiffening in mice.
56. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. New England Journal of Medicine 355: 2283-2296. PMID: 17135583
57. Oliviero U, Bonadies G, Apuzzi V, Foggia M, Bosso G, et al. (2009) Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis 204: 586-589. doi: 10.1016/j.atherosclerosis.2008.10.012 PMID: 19084229
58. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, et al. (2009) Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 23: 1059-1067. doi: 10.1097/QAD.0b013e32832b514b PMID: 19390417
59. Joshi VV, Pawel B, Connor E, Sharer L, Oleske JM, et al. (1987) Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol 7: 261-275. PMID: 3684808
60. Perez-Atayde AR, Kearney DI, Bricker JT, Colan SD, Easley KA, et al. (2004) Cardiac, aortic, and pulmonary arteriopathy in HIV-infected children: the Prospective P2C2 HIV Multicenter Study. Pediatric and developmental pathology: the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 7: 61-70.
61. Paton P, Tabib A, Loire R, Tete R (1993) Coronary artery lesions and human immunodeficiency virus infection. Res Virol 144: 225-231. PMID: 8356344
62. Maniker AH, Hunt CD (1996) Cerebral aneurysm in the HIV patient: a report of six cases. Surg Neurol 46: 49-54. PMID: 8677489
63. Blum A, Hadas V, Burke M, Yust I, Kessler A (2005) Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction. Clin Cardiol 28: 149-153. PMID: 15813624
64. Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S (2004) Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS 18: 1037-1041. PMID: 15096807
65. Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, et al. (2007) Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis.
66. Buchacz K, Weidle P, Moore D, Were W, Mermin J, et al. (2008) Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. Journal of Acquired Immune Deficiency Syndromes 47: 304-311. PMID: 18398971
67. Charakida M, Donald A, Green H, Storry C (2005) Early structural and functional changes of the vasculature in HIV-infected children. Circulation.
68. Estrada V, Portilla J (2011) Dyslipidemia related to antiretroviral therapy. AIDS reviews 13: 49-56. PMID: 21412389
69. Loonam CR, Mullen A (2012) Nutrition and the HIV-associated lipodystrophy syndrome. Nutrition research reviews 25: 267-287. doi: 10.1017/S0954422411000138 PMID: 23174511
70. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. The New England journal of medicine 347: 1557-1565. PMID: 12432042
71. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, et al. (2005) Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middleaged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Archives of Internal Medicine 165: 2479-2484. PMID: 16314544
72. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, et al. (2001) Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke; a journal of cerebral circulation 32: 2575-2579. PMID: 11692019
73. Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, et al. (2005) Increased cardiovascular disease risk indices in HIV-infected women. Journal of acquired immune deficiency syndromes (1999) 39: 44-54. PMID: 15851913
74. Masia M, Bernal E, Padilla S, Graells ML, Jarrin I, et al. (2007) The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 195: 167-171. PMID: 17049532
75. Ross AC, Armentrout R, O'Riordan MA, Storer N, Rizk N, et al. (2008) Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. Journal of acquired immune deficiency syndromes 49: 499-506. doi: 10.1097/QAI.0b013e318189a794 PMID: 18989230
76. Kristoffersen U, Kofoed K, Kronborg G, Giger A, Kjaer A, et al. (2009) Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med 10: 79-87. doi: 10.1111/j.1468-1293.2008.00661.x PMID: 19200170
77. Lichtner M, Cuomo M, Rossi R, Strano S, Massetti A, et al. (2009) Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment. Atherosclerosis 204: e1-3. doi: 10.1016/j.atherosclerosis.2008.12.025 PMID: 19185298
78. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. The Journal of infectious diseases 201: 1788-1795. doi: 10.1086/652749 PMID: 20446848
79. Miller TL, Somarriba G, Orav EJ, Mendez AJ, Neri D, et al. (2010) Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1. Journal of acquired immune deficiency syndromes (1999) 55: 182-188. doi: 10.1097/QAI.0b013e3181e222c9 PMID: 20531209
80. Baker J, Ayenew W, Quick H, Hullsiek K, Tracy R, et al. (2010) High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. Journal of Infectious Diseases 201: 285-292. doi: 10.1086/649560 PMID: 19954384
81. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, et al. (2009) HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 23: 929-939. PMID: 19425222
82. Galkina E, Ley K (2007) Vascular adhesion molecules in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 2292-2301. PMID: 17673705
83. Gattegno L, Bentata-Peyssare M, Gronowski S, Chaouche K, Ferriere F (1995) Elevated concentrations of circulating intercellular adhesion molecule 1 (ICAM-1) and of vascular cell adhesion molecule 1 (VCAM-1) in HIV-1 infection. Cell Adhesion and Communication 3: 179-185. PMID: 8846020
84. Mastroianni CM, Lichtner M, Mengoni F, Agostino C, Ettorre G, et al. (2000) Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients. Clinical immunology (Orlando, Fla) 95: 212-217. PMID: 10866128
85. Matarese G, Mantzoros C, La Cava A (2007) Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Current Pharmaceutical Design 13: 3676-3680. PMID: 18220805
86. Takemura Y, Walsh K, Ouchi N (2007) Adiponectin and cardiovascular inflammatory responses. Current atherosclerosis reports 9: 238-243. PMID: 18241619
87. Gougeon ML, Penicaud L, Fromenty B, Leclercq P, Viard JP, et al. (2004) Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antiviral therapy 9: 161-177. PMID: 15134178